Table 4.

Stratification analysis for the associations of ALKBH3 gene polymorphisms with neuroblastoma risk in children from Jiangsu Province

Variables	rs10768993 (cases/controls)		AOR (95% CI) ^a	P ^a	rs2292889 (cases/controls)		AOR (95% CI) ^a	P ^a	Protective genotypes (cases/controls)		AOR (95% CI) ^a	P ^a
Variables	GG	GA/AA	AOR (95% CI) ^a	P ^a	CC	CG/GG	AOR (95% CI) ^a	P ^a	0–4	5	AOR (95% CI) ^a	P ^a
Age, month
≤ 18	54/46	83/93	0.76 (0.47–1.24)	0.275	128/117	9/22	0.37 (0.17–0.85)	0.018	72/73	65/66	1.00 (0.62–1.61)	0.996
> 18	112/124	151/210	0.80 (0.57–1.11)	0.175	227/286	36/48	0.94 (0.59–1.51)	0.810	163/171	100/163	0.64 (0.46–0.89)	0.009
Gender
Females	80/74	111/151	0.68 (0.46–1.01)	0.058	173/184	18/41	0.47 (0.26–0.84)	0.012	110/113	81/112	0.74 (0.50–1.09)	0.131
Males	86/96	123/152	0.90 (0.62–1.32)	0.597	182/219	27/29	1.12 (0.64–1.96)	0.692	125/131	84/117	0.75 (0.52–1.09)	0.133
Sites of origin
Adrenal gland	34/170	59/303	0.98 (0.62–1.56)	0.936	85/403	8/70	0.55 (0.25–1.18)	0.124	49/244	44/229	0.96 (0.62–1.50)	0.863
Retroperitoneal	68/170	97/303	0.80 (0.55–1.15)	0.221	147/403	18/70	0.70 (0.40–1.22)	0.207	94/244	71/229	0.80 (0.56–1.15)	0.230
Mediastinum	57/170	63/303	0.62 (0.41–0.93)	0.021	103/403	17/70	0.95 (0.54–1.69)	0.870	77/244	43/229	0.60 (0.39–0.90)	0.014
Others	5/170	13/303	1.43 (0.50–4.09)	0.506	16/403	2/70	0.71 (0.16–3.15)	0.647	11/244	7/229	0.68 (0.26–1.77)	0.426
Clinical stages
I + II + 4s	66/170	107/303	0.92 (0.64–1.32)	0.654	150/403	23/70	0.89 (0.53–1.48)	0.646	99/244	74/229	0.80 (0.56–1.14)	0.210
III + IV	70/170	93/303	0.76 (0.53–1.09)	0.132	148/403	15/70	0.59 (0.33–1.07)	0.080	95/244	68/229	0.77 (0.54–1.10)	0.148

AOR, adjusted odds ratio; CI, confidence interval

^a Adjusted for age and gender, omitting the correspondence factor

^b Protective genotypes were carriers with rs11037720 AA/AG, rs1048928 TT/TG, rs10768993 GA/AA, rs2292889 CC/CG, and rs2434474 TC/CC genotypes